98%
921
2 minutes
20
Background And Objective: The obesity paradox is a well-established clinical conundrum in COPD patients. This study aimed to provide an updated analysis of the relationship between body mass index (BMI) and mortality in this population.
Methods: A systematic search was conducted through Embase, PubMed, and Web of Science. International BMI cut-offs were employed to define underweight, overweight and obesity. The primary outcome was all-cause mortality, and the secondary outcome was respiratory and cardiovascular mortality.
Results: 120 studies encompassed a total of 1 053 272 patients. Underweight status was associated with an increased risk of mortality, while overweight and obesity were linked to a reduced risk of mortality. A nonlinear U-shaped relationship was observed between BMI and all-cause mortality, respiratory mortality and cardiovascular mortality. Notably, an inflection point was identified at BMI 28.75 kg·m (relative risk 0.83, 95% CI 0.80-0.86), 30.25 kg·m (relative risk 0.51, 95% CI 0.40-0.65) and 27.5 kg·m (relative risk 0.76, 95% CI 0.64-0.91) for all-cause, respiratory and cardiovascular mortality, respectively, and beyond which the protective effect began to diminish.
Conclusion: This study augments the existing body of evidence by confirming a U-shaped relationship between BMI and mortality in COPD patients. It underscores the heightened influence of BMI on respiratory and cardiovascular mortality compared to all-cause mortality. The protective effect of BMI was lost when BMI values exceeded 35.25 kg·m, 35 kg·m and 31 kg·m for all-cause, respiratory and cardiovascular mortality, respectively.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11600125 | PMC |
http://dx.doi.org/10.1183/16000617.0261-2023 | DOI Listing |
Radiology
September 2025
Department of Diagnostic, Molecular, and Interventional Radiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Plc, Box 1234, New York, NY 10029.
Background The prognostic value of baseline visual emphysema scoring at low-dose CT (LDCT) in lung cancer screening cohorts is unknown. Purpose To determine whether a single visual emphysema score at LDCT is predictive of 25-year mortality from all causes, chronic obstructive pulmonary disease (COPD), and cardiovascular disease (CVD). Materials and Methods In this prospective cohort study, asymptomatic adults aged 40-85 years with a history of smoking underwent baseline LDCT screening for lung cancer between June 2000 and December 2008.
View Article and Find Full Text PDFEndocr Connect
September 2025
Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Objective: Characterize disease-specific mortality rates in patients with acromegaly on pegvisomant and identify pertinent risk factors, including on-therapy insulin-like growth factor I (IGF-I) levels.
Design: Retrospective cohort analysis of ACROSTUDY, a global surveillance study of patients with acromegaly receiving pegvisomant.
Methods: Cumulative incidence function to estimate disease-specific mortality and regression analyses to characterize risk factors.
Angew Chem Int Ed Engl
September 2025
Department of Chemistry, Korea University, Seoul, 02841, South Korea.
Chemodynamic therapy (CDT), leveraging Fenton reactions to generate hydroxyl radicals (•OH) from intracellular hydrogen peroxide (HO), offers a promising cancer treatment strategy due to its high specificity and low systemic toxicity. However, the targeted delivery of •OH-producing prodrugs using covalent organic frameworks (COFs) remains a significant challenge. Here, we report a mitochondria-targeted COF-based nano prodrug, COF-31@P, designed for enhanced CDT efficacy.
View Article and Find Full Text PDFDrug Des Devel Ther
September 2025
Department of Anesthesiology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, People's Republic of China.
Purpose: Neoadjuvant immunochemotherapy (NICT) has shown promise in improving the oncological outcomes of locally advanced esophageal cancer (LAEC). However, concerns remain regarding its potential to induce pulmonary side effects that may increase the risk of perioperative adverse events. This study aimed to compare the incidence of postoperative pulmonary complications (PPCs) in patients receiving NICT and those undergoing non-neoadjuvant therapy.
View Article and Find Full Text PDF